Bristol John W & Co. Inc. NY boosted its position in shares of Novartis AG (NYSE:NVS) by 10.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 868,278 shares of the company’s stock after buying an additional 81,730 shares during the period. Novartis AG makes up approximately 1.9% of Bristol John W & Co. Inc. NY’s portfolio, making the stock its 24th largest position. Bristol John W & Co. Inc. NY’s holdings in Novartis AG were worth $68,559,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Iowa State Bank purchased a new stake in shares of Novartis AG during the second quarter worth approximately $122,000. Gardiner Nancy B increased its stake in shares of Novartis AG by 12.1% in the first quarter. Gardiner Nancy B now owns 8,225 shares of the company’s stock worth $596,000 after buying an additional 885 shares in the last quarter. Lebenthal Asset Management LLC purchased a new stake in shares of Novartis AG during the first quarter worth approximately $3,580,000. Cullinan Associates Inc. increased its stake in shares of Novartis AG by 44.0% in the first quarter. Cullinan Associates Inc. now owns 3,600 shares of the company’s stock worth $261,000 after buying an additional 1,100 shares in the last quarter. Finally, First Republic Investment Management Inc. increased its stake in shares of Novartis AG by 16.7% in the first quarter. First Republic Investment Management Inc. now owns 582,186 shares of the company’s stock worth $42,173,000 after buying an additional 83,122 shares in the last quarter. 9.85% of the stock is currently owned by institutional investors.

Institutional Ownership by Quarter for Novartis AG (NYSE:NVS)

Novartis AG (NYSE:NVS) traded down 0.72% during mid-day trading on Monday, hitting $70.13. 2,805,530 shares of the stock traded hands. The stock has a 50-day moving average of $74.05 and a 200 day moving average of $78.55. Novartis AG has a 1-year low of $69.84 and a 1-year high of $88.49. The firm has a market cap of $166.60 billion, a price-to-earnings ratio of 24.73 and a beta of 0.71.

Novartis AG (NYSE:NVS) last posted its quarterly earnings results on Tuesday, October 25th. The company reported $1.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.19 by $0.04. The firm had revenue of $12.13 billion for the quarter, compared to analysts’ expectations of $12.24 billion. Novartis AG had a net margin of 13.98% and a return on equity of 15.25%. The firm’s quarterly revenue was down 1.1% on a year-over-year basis. During the same period in the prior year, the company posted $1.27 earnings per share. On average, equities analysts expect that Novartis AG will post $4.72 EPS for the current year.

A number of brokerages have commented on NVS. Zacks Investment Research downgraded shares of Novartis AG from a “hold” rating to a “sell” rating in a research report on Wednesday, September 21st. Argus reaffirmed a “hold” rating on shares of Novartis AG in a research report on Thursday, August 25th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Novartis AG in a research report on Tuesday, September 13th. Chardan Capital started coverage on shares of Novartis AG in a research report on Tuesday, September 20th. They issued a “buy” rating and a $95.00 target price on the stock. Finally, TheStreet downgraded shares of Novartis AG from a “buy” rating to a “hold” rating in a research report on Wednesday, September 28th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $88.50.

Novartis AG Company Profile

Novartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care and generic pharmaceuticals. The Company’s segments include Pharmaceuticals, Alcon and Sandoz.

5 Day Chart for NYSE:NVS

Receive News & Stock Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related stocks with our FREE daily email newsletter.